XML 89 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions and divestitures - Teneobio Inc. (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
program
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]        
Goodwill, adjustment   $ 3,089 $ 651  
Additions   0 0 $ 309
Goodwill $ 15,529 18,629 15,529 $ 14,890
Teneobio        
Business Acquisition [Line Items]        
Goodwill, adjustment   $ 22    
Cash purchase price 993      
Maximum additional consideration due contingent on certain milestones 1,600   1,600  
Additions 299      
Deferred tax liabilities 244   244  
Goodwill 273   273  
Teneobio | R & D Technology rights        
Business Acquisition [Line Items]        
Finite-lived intangible assets acquired $ 115      
Weighted average period of amortization 10 years      
Teneobio | Licensing rights        
Business Acquisition [Line Items]        
Finite-lived intangible assets acquired $ 41      
Teneobio | IPR&D        
Business Acquisition [Line Items]        
Acquired in-process research and development 991   991  
Number of oncology programs comprising remaining IPR&D | program   4    
Teneobio | IPR&D | AMG 340        
Business Acquisition [Line Items]        
Acquired in-process research and development $ 784   $ 784